NSE: GPTHEALTH · BSE: 544131 · ISIN INE486R01017
GPT Healthcare Limited stock analysis
GPT Healthcare Limited ranks #847 in the TickerSutra evidence-ranked universe with a score of 59/100 and 89% data confidence. The latest captured fundamentals show ROCE of 19.9%, quarterly sales growth of 17.8% and quarterly profit growth of 65.8%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Strong CFO/EBITDA of 0.95×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹337cr | ₹74cr | ₹42cr | 22.0% |
| 2023 | ₹361cr | ₹74cr | ₹39cr | 21.0% |
| 2024 | ₹400cr | ₹88cr | ₹48cr | 22.0% |
| 2025 | ₹407cr | ₹83cr | ₹50cr | 20.0% |
| 2026 | ₹473cr | ₹85cr | ₹42cr | 18.0% |
| TTM | ₹492cr | ₹91cr | ₹47cr | 19.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
GPT Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineGPT Healthcare Ltd - 544131 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE · 21 Sept 2026Please find enclosed herewith the Intimation for Analyst/Investor meeting to be held on September 28, 2026.
MANAGEMENT COMMENTARY
Signals from filed documents
So going ahead, do you see like INR50 crores run rate on the EBITDA, which would obviously translate to INR110 crores, INR120 crores of EBITDA annually? Do you see that because our ARPOBs are increasing and our occupancy is increasing, which should give us an operating leverage? Anurag Tantia: We expect the EBITDA levels to improve compared to last year on account of better occupancy of mature hospitals and the reduc
On the clinical side, Agartala has launched comprehensive cancer care with PET scan and Linear Accelerator capabilities, while Howrah has commenced robotic knee replacement surgeries expected to increase ARPOB and reduce average length of stay. Occupancy ramp-up at Agartala and Howrah to approximately 70% remains a near-term priority, with meaningful margin expansion expected as utilisation improves. Om T antia Chair
Supported by its strategic location and asse t-light operating model, Raipur remains on track to achieve operational breakeven while steadily expanding its reach across the surrounding catchment area. Our expansion plans also continue to progress well. Construction of our 155 -bed tertiary care hospital at Jamshedpur remains on schedule and is expected to be commissioned during Q4 FY27.
I also extend my sincere gratitude to our patients, shareholders, lenders, business partners and al l other stakeholders for their continued trust and support. With a strong presence, a growing network and a clear road map for expansion, we are confident of creating sustainable long-term value while strengthening our position as a leading health care provider in Eastern India. With that, I conclude my opening remarks
Just a follow -up on previous participant's question. You've explained the occupancy dip in Agartala, but this blended increase that you've seen in ARPOB for Agartala and Howrah both, is it majorly because of the new high-end treatments or you took calibrated price increases across all treatments? Anurag Tantia: We have not had any tariff increase in any of our hospitals.
Regulatory Risks Risk Description Mitigation Regulatory & licensing Changes to healthcare regulations or accreditation standards may require operational adjustments and increase compliance costs. The Company maintains a dedicated compliance function, conducts regular regulatory reviews, and has established proactive engagement with relevant authorities to adapt to policy changes. Data privacy & patient rights Non-com
Any future changes in the SEBI Listing Regulations or the Act will, ipso facto, apply to this Policy. The Policy has been amended and approved by the Nomination and Remuneration Committee and the Board of Directors in their meetings held on May 23, 2025. OBJECTIVE: The Key Objectives of the Committee would be: a.
2 1 (180.47) 6 .74 355.50 (324.52) 30.98 2 to 3 Years 91.76 (91.76) - - - - More than 3 years - - - - - - 2,300.65 (272.23) 2,028.42 2,294.42 (324.52) 1,969.90 Customer Concentration: No single customer represents 10% or more of the Company’s total revenue during the year ended 31 March 2026 and 31 March 2025. Therefore the customer concentration risk is limited due to the large and unrelated customer base. Credit ri
News releases, presentations, etc.: Official news releases and official media releases are sent to Stock Exchanges and are displayed on Company’s website. Presentations to institutional investors / analysts: These presentations and Schedule of analyst or institutional investors meet are also uploaded on the Company’s website (www.ilshospitals.com) as well as sent to the Stock Exchanges. No unpublished price sensitive
So there might be - - if the approvals come in place, we are hopeful of starting that. But in case of any delay in approvals, it might be pushed to first -- the beginning of next year. Moderator: The next question is from the line of Soumya Raghuvanshi from Nirva Securities.
Actual results could differ from those expressed or implied. Important factors that could make a difference to the Company’s operations include economic conditions affecting demand, supply, and price conditions in the domestic & overseas markets in which the Company operates, changes in Government regulations, tax laws & other statutes, and other incidental factors. The Company assumes no responsibility in respect of
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…